Inhibikase Therapeutics, Inc. (IKT) 10-Year Financial Performance & Capital Metrics

IKT • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutInhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.Show more

Revenue $0 -100.0%
EBITDA -$29M -43.4%
Net Income -$28M -44.6%
EPS (Diluted) -1.16 +67.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -52% +56.3%
ROIC -104.8% +42.2%
Debt/Equity 0.00 -97.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.2x book value

✗Weaknesses

✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-143.58%

EPS CAGR

10Y-

5Y-

3Y-

TTM79.32%

ROCE

10Y Avg-79.29%

5Y Avg-79.29%

3Y Avg-79.7%

Latest-53.98%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	967.39K	2.06M	4.04M	1.12M	698.47K	3.1M	123.44K	260.5K	0
Revenue Growth %	-	1.13%	0.96%	-0.72%	-0.38%	3.44%	-0.96%	1.11%	-1%
Cost of Goods Sold+	846.39K	1.76M	3.65M	2.55M	893.8K	11.36M	6.72K	13.62M	26.27K
COGS % of Revenue	0.87%	0.85%	0.9%	2.27%	1.28%	3.66%	0.05%	52.28%	-
Gross Profit+	121K	305.25K	393.85K	-1.43M	-195.33K	-8.26M	116.72K	-13.36M	-26.27K
Gross Margin %	0.13%	0.15%	0.1%	-1.27%	-0.28%	-2.66%	0.95%	-51.28%	-
Gross Profit Growth %	-	1.52%	0.29%	-4.63%	0.86%	-41.28%	1.01%	-115.45%	1%
Operating Expenses+	734.29K	2.47M	2.12M	4.27M	2.62M	6.51M	18.25M	6.73M	28.56M
OpEx % of Revenue	0.76%	1.2%	0.53%	3.8%	3.76%	2.1%	147.81%	25.84%	-
Selling, General & Admin	734.29K	710.38K	2.52M	0	0	0	6.21M	6.73M	11.38M
SG&A % of Revenue	0.76%	0.34%	0.62%	-	-	-	50.31%	25.84%	-
Research & Development	846.39K	1.76M	3.65M	2.55M	893.8K	11.36M	12.03M	13.62M	17.21M
R&D % of Revenue	0.87%	0.85%	0.9%	2.27%	1.28%	3.66%	97.5%	52.28%	-
Other Operating Expenses	0	0	0	1.72M	1.73M	-4.85M	0	-13.62M	-26.27K
Operating Income+	-613.29K	-405.13K	-2.12M	-5.7M	-2.82M	-14.77M	-18.13M	-20.09M	-28.59M
Operating Margin %	-0.63%	-0.2%	-0.53%	-5.08%	-4.04%	-4.76%	-146.86%	-77.12%	-
Operating Income Growth %	-	0.34%	-4.24%	-1.69%	0.51%	-4.24%	-0.23%	-0.11%	-0.42%
EBITDA+	0	0	0	0	0	0	-18.12M	-19.91M	-28.56M
EBITDA Margin %	-	-	-	-	-	-	-146.81%	-76.44%	-
EBITDA Growth %	-	-	-	-	-	-	-	-0.1%	-0.43%
D&A (Non-Cash Add-back)	613.29K	405.13K	2.12M	5.7M	2.82M	14.77M	6.72K	177.4K	26.27K
EBIT	-613.29K	-405.13K	-2.12M	-5.7M	-2.82M	-14.77M	-18.05M	-20.09M	-27.52M
Net Interest Income+	0	0	0	0	0	0	0	1.06M	1.07M
Interest Income	15.45K	30.95K	0	24.84K	29.4K	19.92K	74.45K	1.06M	1.07M
Interest Expense	0	0	30.33K	24.84K	29.4K	19.92K	74.45K	0	0
Other Income/Expense	-15.45K	-30.95K	-30.33K	-24.84K	-29.4K	-19.92K	74.45K	1.06M	1.07M
Pretax Income+	-628.74K	-436.07K	-2.15M	-5.72M	-2.85M	-14.79M	-18.05M	-19.03M	-27.52M
Pretax Margin %	-0.65%	-0.21%	-0.53%	-5.1%	-4.08%	-4.77%	-146.26%	-73.05%	-
Income Tax+	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-628.74K	-436.07K	-2.15M	-5.72M	-2.85M	-14.79M	-18.05M	-19.03M	-27.52M
Net Margin %	-0.65%	-0.21%	-0.53%	-5.1%	-4.08%	-4.77%	-146.26%	-73.05%	-
Net Income Growth %	-	0.31%	-3.94%	-1.66%	0.5%	-4.19%	-0.22%	-0.05%	-0.45%
Net Income (Continuing)	-628.74K	-436.07K	-2.15M	-5.72M	-2.85M	-14.79M	-18.05M	-19.03M	-27.52M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.48	-0.25	-1.61	-3.34	-1.72	-4.88	-4.26	-3.57	-1.16
EPS Growth %	-	0.48%	-5.44%	-1.07%	0.49%	-1.84%	0.13%	0.16%	0.68%
EPS (Basic)	-0.48	-0.25	-1.61	-3.34	-1.72	-4.88	-4.26	-3.57	-1.16
Diluted Shares Outstanding	1.3M	1.72M	1.34M	1.72M	1.68M	3.03M	4.2M	5.33M	69.36M
Basic Shares Outstanding	1.3M	1.72M	1.34M	1.72M	1.68M	3.03M	4.2M	5.33M	69.36M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	80.16K	198.07K	1.25M	35.38K	14.78M	42.47M	24.37M	14.21M	98.45M
Cash & Short-Term Investments	12.04K	16.66K	379.56K	18.46K	13.95M	40.75M	23.05M	13.25M	97.54M
Cash Only	12.04K	16.66K	379.56K	18.46K	13.95M	40.75M	7.19M	9.17M	56.49M
Short-Term Investments	0	0	0	0	0	0	15.86M	4.09M	41.05M
Accounts Receivable	66.88K	180.78K	472.94K	0	0	110.14K	39.88K	0	0
Days Sales Outstanding	25.23	32.02	42.72	-	-	12.97	117.92	-	-
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	0	-	-	-	-	-	-	-	-
Other Current Assets	0	625	0	16.92K	54.84K	107K	1.12M	739.18K	106.31K
Total Non-Current Assets+	82.76K	87.1K	1.59M	2.87K	0	0	565.17K	295.6K	148.54K
Property, Plant & Equipment	0	0	0	0	0	0	565.17K	295.6K	148.54K
Fixed Asset Turnover	-	-	-	-	-	-	0.22x	0.88x	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	87.1K	0	0	0	0	0	0	0
Other Non-Current Assets	82.76K	0	1.59M	2.87K	0	0	0	0	0
Total Assets+	162.93K	285.17K	2.85M	38.25K	14.78M	42.47M	24.94M	14.51M	98.6M
Asset Turnover	5.94x	7.23x	1.42x	29.35x	0.05x	0.07x	0.00x	0.02x	-
Asset Growth %	-	0.75%	8.98%	-0.99%	385.44%	1.87%	-0.41%	-0.42%	5.8%
Total Current Liabilities+	1.51M	1.73M	3.62M	4.25M	4.72M	4.05M	3.7M	3.44M	3.73M
Accounts Payable	431.79K	353.52K	954.24K	1M	1.72M	1.09M	1.15M	646.77K	943.02K
Days Payables Outstanding	186.21	73.5	95.5	143.23	702.67	35.02	62.5K	17.33	13.1K
Short-Term Debt	328.94K	459.96K	233.73K	98.42K	42.53K	248.91K	0	381.78K	0
Deferred Revenue (Current)	0	5.64K	262.37K	1000K	1000K	0	0	0	0
Other Current Liabilities	0	907.05K	0	0	0	0	0	635.45K	0
Current Ratio	0.05x	0.11x	0.35x	0.01x	3.13x	10.47x	6.59x	4.13x	26.37x
Quick Ratio	0.05x	0.11x	0.35x	0.01x	3.13x	10.47x	6.59x	4.13x	26.37x
Cash Conversion Cycle	-160.97	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	1.45M	275.38K	276.46K	0	205.45K	90.12K	0
Long-Term Debt	0	0	0	275.38K	276.46K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	205.45K	90.12K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0
Total Liabilities	1.51M	1.73M	3.62M	4.53M	5M	4.05M	3.9M	3.53M	3.73M
Total Debt+	328.94K	459.96K	233.73K	373.79K	319K	248.91K	351.29K	622K	110.52K
Net Debt	316.91K	443.3K	-145.83K	355.34K	-13.63M	-40.5M	-6.84M	-8.54M	-56.38M
Debt / Equity	-	-	-	-	0.03x	0.01x	0.02x	0.06x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-69.96x	-229.44x	-95.86x	-741.16x	-243.49x	-	-
Total Equity+	-1.35M	-1.44M	-777.97K	-4.49M	9.78M	38.42M	21.04M	10.98M	94.87M
Equity Growth %	-	-0.07%	0.46%	-4.77%	3.18%	2.93%	-0.45%	-0.48%	7.64%
Book Value per Share	-1.04	-0.84	-0.58	-2.61	5.84	12.66	5.01	2.06	1.37
Total Shareholders' Equity	-1.35M	-1.44M	-777.97K	-4.49M	9.78M	38.42M	21.04M	10.98M	94.87M
Common Stock	8.92K	8.92K	8.18K	8.18K	10.05K	25.16K	4.22K	6.19K	69.36K
Retained Earnings	-3.87M	-4.31M	-6.46M	-12.18M	-15.03M	-29.82M	-47.87M	-66.9M	-94.42M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	104.72K	877	-37.25K
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-29.57K	-126.39K	714.99K	-338.29K	-1.13M	-14.3M	-17.35M	-18.09M	-19.15M
Operating CF Margin %	-0.03%	-0.06%	0.18%	-0.3%	-1.62%	-4.61%	-140.56%	-69.42%	-
Operating CF Growth %	-	-3.27%	6.66%	-1.47%	-2.34%	-11.66%	-0.21%	-0.04%	-0.06%
Net Income	-628.74K	-436.07K	-2.15M	-5.72M	-2.85M	-14.79M	-18.05M	-19.03M	-27.52M
Depreciation & Amortization	0	0	0	0	0	0	6.72K	177.4K	26.27K
Stock-Based Compensation	310.09K	300.66K	642.23K	1.44M	573.7K	1.53M	458.15K	500.15K	8.14M
Deferred Taxes	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	95.71K	534.62K	709.27K	2.32M	1.61M	721.63K	67K	31.54K	0
Working Capital Changes	193.36K	-32.76K	1.52M	1.63M	-464.64K	-1.76M	171.18K	234.76K	204.93K
Change in Receivables	94.45K	-113.9K	-292.16K	472.94K	0	-110.14K	70.26K	39.88K	0
Change in Inventory	0	0	950.65K	-54.9K	0	1.3M	0	0	0
Change in Payables	0	-78.27K	600.72K	47.46K	-247.07K	-630.9K	61.4K	-504.41K	271.78K
Cash from Investing+	0	0	87.1K	0	0	0	-16.01M	11.66M	-37M
Capital Expenditures	0	0	0	0	0	0	-243.25K	-14.24K	0
CapEx % of Revenue	-	-	-	-	-	-	1.97%	0.05%	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	87.1K	0	0	0	-243.25K	0	0
Cash from Financing+	-23.77K	131.02K	-439.19K	-22.81K	15.06M	41.09M	-204.77K	8.41M	103.48M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	-23.77K	131.02K	-1.59M	0	0	848	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-29.57K	-126.39K	714.99K	-338.29K	-1.13M	-14.3M	-17.59M	-18.1M	-19.15M
FCF Margin %	-0.03%	-0.06%	0.18%	-0.3%	-1.62%	-4.61%	-142.53%	-69.48%	-
FCF Growth %	-	-3.27%	6.66%	-1.47%	-2.34%	-11.66%	-0.23%	-0.03%	-0.06%
FCF per Share	-0.02	-0.07	0.54	-0.20	-0.67	-4.71	-4.19	-3.39	-0.28
FCF Conversion (FCF/Net Income)	0.05x	0.29x	-0.33x	0.06x	0.40x	0.97x	0.96x	0.95x	0.70x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-107.58%	-61.35%	-60.74%	-118.88%	-52%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-224.5%	-181.18%	-104.8%
Gross Margin	12.51%	14.81%	9.75%	-127.36%	-27.97%	-266.35%	94.55%	-5127.77%	-
Net Margin	-64.99%	-21.16%	-53.27%	-509.73%	-407.73%	-476.88%	-14625.85%	-7304.75%	-
Debt / Equity	-	-	-	-	0.03x	0.01x	0.02x	0.06x	0.00x
Interest Coverage	-	-	-69.96x	-229.44x	-95.86x	-741.16x	-243.49x	-	-
FCF Conversion	0.05x	0.29x	-0.33x	0.06x	0.40x	0.97x	0.96x	0.95x	0.70x
Revenue Growth	-	113.04%	96.07%	-72.22%	-37.79%	343.92%	-96.02%	111.03%	-100%

Frequently Asked Questions

Growth & Financials

Inhibikase Therapeutics, Inc. (IKT) saw revenue decline by 100.0% over the past year.

Inhibikase Therapeutics, Inc. (IKT) reported a net loss of $47.7M for fiscal year 2024.

Dividend & Returns

Inhibikase Therapeutics, Inc. (IKT) has a return on equity (ROE) of -52.0%. Negative ROE indicates the company is unprofitable.

Inhibikase Therapeutics, Inc. (IKT) had negative free cash flow of $25.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Inhibikase Therapeutics, Inc. (IKT) 10-Year Financial Performance & Capital Metrics

IKT • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

Revenue $0 -100.0%
EBITDA -$29M -43.4%
Net Income -$28M -44.6%
EPS (Diluted) -1.16 +67.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -52% +56.3%
ROIC -104.8% +42.2%
Debt/Equity 0.00 -97.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.2x book value

✗Weaknesses

✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-143.58%

EPS CAGR

10Y-

5Y-

3Y-

TTM79.32%

ROCE

10Y Avg-79.29%

5Y Avg-79.29%

3Y Avg-79.7%

Latest-53.98%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	967.39K	2.06M	4.04M	1.12M	698.47K	3.1M	123.44K	260.5K	0
Revenue Growth %	-	1.13%	0.96%	-0.72%	-0.38%	3.44%	-0.96%	1.11%	-1%
Cost of Goods Sold+	846.39K	1.76M	3.65M	2.55M	893.8K	11.36M	6.72K	13.62M	26.27K
COGS % of Revenue	0.87%	0.85%	0.9%	2.27%	1.28%	3.66%	0.05%	52.28%	-
Gross Profit+	121K	305.25K	393.85K	-1.43M	-195.33K	-8.26M	116.72K	-13.36M	-26.27K
Gross Margin %	0.13%	0.15%	0.1%	-1.27%	-0.28%	-2.66%	0.95%	-51.28%	-
Gross Profit Growth %	-	1.52%	0.29%	-4.63%	0.86%	-41.28%	1.01%	-115.45%	1%
Operating Expenses+	734.29K	2.47M	2.12M	4.27M	2.62M	6.51M	18.25M	6.73M	28.56M
OpEx % of Revenue	0.76%	1.2%	0.53%	3.8%	3.76%	2.1%	147.81%	25.84%	-
Selling, General & Admin	734.29K	710.38K	2.52M	0	0	0	6.21M	6.73M	11.38M
SG&A % of Revenue	0.76%	0.34%	0.62%	-	-	-	50.31%	25.84%	-
Research & Development	846.39K	1.76M	3.65M	2.55M	893.8K	11.36M	12.03M	13.62M	17.21M
R&D % of Revenue	0.87%	0.85%	0.9%	2.27%	1.28%	3.66%	97.5%	52.28%	-
Other Operating Expenses	0	0	0	1.72M	1.73M	-4.85M	0	-13.62M	-26.27K
Operating Income+	-613.29K	-405.13K	-2.12M	-5.7M	-2.82M	-14.77M	-18.13M	-20.09M	-28.59M
Operating Margin %	-0.63%	-0.2%	-0.53%	-5.08%	-4.04%	-4.76%	-146.86%	-77.12%	-
Operating Income Growth %	-	0.34%	-4.24%	-1.69%	0.51%	-4.24%	-0.23%	-0.11%	-0.42%
EBITDA+	0	0	0	0	0	0	-18.12M	-19.91M	-28.56M
EBITDA Margin %	-	-	-	-	-	-	-146.81%	-76.44%	-
EBITDA Growth %	-	-	-	-	-	-	-	-0.1%	-0.43%
D&A (Non-Cash Add-back)	613.29K	405.13K	2.12M	5.7M	2.82M	14.77M	6.72K	177.4K	26.27K
EBIT	-613.29K	-405.13K	-2.12M	-5.7M	-2.82M	-14.77M	-18.05M	-20.09M	-27.52M
Net Interest Income+	0	0	0	0	0	0	0	1.06M	1.07M
Interest Income	15.45K	30.95K	0	24.84K	29.4K	19.92K	74.45K	1.06M	1.07M
Interest Expense	0	0	30.33K	24.84K	29.4K	19.92K	74.45K	0	0
Other Income/Expense	-15.45K	-30.95K	-30.33K	-24.84K	-29.4K	-19.92K	74.45K	1.06M	1.07M
Pretax Income+	-628.74K	-436.07K	-2.15M	-5.72M	-2.85M	-14.79M	-18.05M	-19.03M	-27.52M
Pretax Margin %	-0.65%	-0.21%	-0.53%	-5.1%	-4.08%	-4.77%	-146.26%	-73.05%	-
Income Tax+	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-628.74K	-436.07K	-2.15M	-5.72M	-2.85M	-14.79M	-18.05M	-19.03M	-27.52M
Net Margin %	-0.65%	-0.21%	-0.53%	-5.1%	-4.08%	-4.77%	-146.26%	-73.05%	-
Net Income Growth %	-	0.31%	-3.94%	-1.66%	0.5%	-4.19%	-0.22%	-0.05%	-0.45%
Net Income (Continuing)	-628.74K	-436.07K	-2.15M	-5.72M	-2.85M	-14.79M	-18.05M	-19.03M	-27.52M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.48	-0.25	-1.61	-3.34	-1.72	-4.88	-4.26	-3.57	-1.16
EPS Growth %	-	0.48%	-5.44%	-1.07%	0.49%	-1.84%	0.13%	0.16%	0.68%
EPS (Basic)	-0.48	-0.25	-1.61	-3.34	-1.72	-4.88	-4.26	-3.57	-1.16
Diluted Shares Outstanding	1.3M	1.72M	1.34M	1.72M	1.68M	3.03M	4.2M	5.33M	69.36M
Basic Shares Outstanding	1.3M	1.72M	1.34M	1.72M	1.68M	3.03M	4.2M	5.33M	69.36M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	80.16K	198.07K	1.25M	35.38K	14.78M	42.47M	24.37M	14.21M	98.45M
Cash & Short-Term Investments	12.04K	16.66K	379.56K	18.46K	13.95M	40.75M	23.05M	13.25M	97.54M
Cash Only	12.04K	16.66K	379.56K	18.46K	13.95M	40.75M	7.19M	9.17M	56.49M
Short-Term Investments	0	0	0	0	0	0	15.86M	4.09M	41.05M
Accounts Receivable	66.88K	180.78K	472.94K	0	0	110.14K	39.88K	0	0
Days Sales Outstanding	25.23	32.02	42.72	-	-	12.97	117.92	-	-
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	0	-	-	-	-	-	-	-	-
Other Current Assets	0	625	0	16.92K	54.84K	107K	1.12M	739.18K	106.31K
Total Non-Current Assets+	82.76K	87.1K	1.59M	2.87K	0	0	565.17K	295.6K	148.54K
Property, Plant & Equipment	0	0	0	0	0	0	565.17K	295.6K	148.54K
Fixed Asset Turnover	-	-	-	-	-	-	0.22x	0.88x	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	87.1K	0	0	0	0	0	0	0
Other Non-Current Assets	82.76K	0	1.59M	2.87K	0	0	0	0	0
Total Assets+	162.93K	285.17K	2.85M	38.25K	14.78M	42.47M	24.94M	14.51M	98.6M
Asset Turnover	5.94x	7.23x	1.42x	29.35x	0.05x	0.07x	0.00x	0.02x	-
Asset Growth %	-	0.75%	8.98%	-0.99%	385.44%	1.87%	-0.41%	-0.42%	5.8%
Total Current Liabilities+	1.51M	1.73M	3.62M	4.25M	4.72M	4.05M	3.7M	3.44M	3.73M
Accounts Payable	431.79K	353.52K	954.24K	1M	1.72M	1.09M	1.15M	646.77K	943.02K
Days Payables Outstanding	186.21	73.5	95.5	143.23	702.67	35.02	62.5K	17.33	13.1K
Short-Term Debt	328.94K	459.96K	233.73K	98.42K	42.53K	248.91K	0	381.78K	0
Deferred Revenue (Current)	0	5.64K	262.37K	1000K	1000K	0	0	0	0
Other Current Liabilities	0	907.05K	0	0	0	0	0	635.45K	0
Current Ratio	0.05x	0.11x	0.35x	0.01x	3.13x	10.47x	6.59x	4.13x	26.37x
Quick Ratio	0.05x	0.11x	0.35x	0.01x	3.13x	10.47x	6.59x	4.13x	26.37x
Cash Conversion Cycle	-160.97	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	1.45M	275.38K	276.46K	0	205.45K	90.12K	0
Long-Term Debt	0	0	0	275.38K	276.46K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	205.45K	90.12K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0
Total Liabilities	1.51M	1.73M	3.62M	4.53M	5M	4.05M	3.9M	3.53M	3.73M
Total Debt+	328.94K	459.96K	233.73K	373.79K	319K	248.91K	351.29K	622K	110.52K
Net Debt	316.91K	443.3K	-145.83K	355.34K	-13.63M	-40.5M	-6.84M	-8.54M	-56.38M
Debt / Equity	-	-	-	-	0.03x	0.01x	0.02x	0.06x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-69.96x	-229.44x	-95.86x	-741.16x	-243.49x	-	-
Total Equity+	-1.35M	-1.44M	-777.97K	-4.49M	9.78M	38.42M	21.04M	10.98M	94.87M
Equity Growth %	-	-0.07%	0.46%	-4.77%	3.18%	2.93%	-0.45%	-0.48%	7.64%
Book Value per Share	-1.04	-0.84	-0.58	-2.61	5.84	12.66	5.01	2.06	1.37
Total Shareholders' Equity	-1.35M	-1.44M	-777.97K	-4.49M	9.78M	38.42M	21.04M	10.98M	94.87M
Common Stock	8.92K	8.92K	8.18K	8.18K	10.05K	25.16K	4.22K	6.19K	69.36K
Retained Earnings	-3.87M	-4.31M	-6.46M	-12.18M	-15.03M	-29.82M	-47.87M	-66.9M	-94.42M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	104.72K	877	-37.25K
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-29.57K	-126.39K	714.99K	-338.29K	-1.13M	-14.3M	-17.35M	-18.09M	-19.15M
Operating CF Margin %	-0.03%	-0.06%	0.18%	-0.3%	-1.62%	-4.61%	-140.56%	-69.42%	-
Operating CF Growth %	-	-3.27%	6.66%	-1.47%	-2.34%	-11.66%	-0.21%	-0.04%	-0.06%
Net Income	-628.74K	-436.07K	-2.15M	-5.72M	-2.85M	-14.79M	-18.05M	-19.03M	-27.52M
Depreciation & Amortization	0	0	0	0	0	0	6.72K	177.4K	26.27K
Stock-Based Compensation	310.09K	300.66K	642.23K	1.44M	573.7K	1.53M	458.15K	500.15K	8.14M
Deferred Taxes	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	95.71K	534.62K	709.27K	2.32M	1.61M	721.63K	67K	31.54K	0
Working Capital Changes	193.36K	-32.76K	1.52M	1.63M	-464.64K	-1.76M	171.18K	234.76K	204.93K
Change in Receivables	94.45K	-113.9K	-292.16K	472.94K	0	-110.14K	70.26K	39.88K	0
Change in Inventory	0	0	950.65K	-54.9K	0	1.3M	0	0	0
Change in Payables	0	-78.27K	600.72K	47.46K	-247.07K	-630.9K	61.4K	-504.41K	271.78K
Cash from Investing+	0	0	87.1K	0	0	0	-16.01M	11.66M	-37M
Capital Expenditures	0	0	0	0	0	0	-243.25K	-14.24K	0
CapEx % of Revenue	-	-	-	-	-	-	1.97%	0.05%	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	87.1K	0	0	0	-243.25K	0	0
Cash from Financing+	-23.77K	131.02K	-439.19K	-22.81K	15.06M	41.09M	-204.77K	8.41M	103.48M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	-23.77K	131.02K	-1.59M	0	0	848	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-29.57K	-126.39K	714.99K	-338.29K	-1.13M	-14.3M	-17.59M	-18.1M	-19.15M
FCF Margin %	-0.03%	-0.06%	0.18%	-0.3%	-1.62%	-4.61%	-142.53%	-69.48%	-
FCF Growth %	-	-3.27%	6.66%	-1.47%	-2.34%	-11.66%	-0.23%	-0.03%	-0.06%
FCF per Share	-0.02	-0.07	0.54	-0.20	-0.67	-4.71	-4.19	-3.39	-0.28
FCF Conversion (FCF/Net Income)	0.05x	0.29x	-0.33x	0.06x	0.40x	0.97x	0.96x	0.95x	0.70x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-107.58%	-61.35%	-60.74%	-118.88%	-52%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-224.5%	-181.18%	-104.8%
Gross Margin	12.51%	14.81%	9.75%	-127.36%	-27.97%	-266.35%	94.55%	-5127.77%	-
Net Margin	-64.99%	-21.16%	-53.27%	-509.73%	-407.73%	-476.88%	-14625.85%	-7304.75%	-
Debt / Equity	-	-	-	-	0.03x	0.01x	0.02x	0.06x	0.00x
Interest Coverage	-	-	-69.96x	-229.44x	-95.86x	-741.16x	-243.49x	-	-
FCF Conversion	0.05x	0.29x	-0.33x	0.06x	0.40x	0.97x	0.96x	0.95x	0.70x
Revenue Growth	-	113.04%	96.07%	-72.22%	-37.79%	343.92%	-96.02%	111.03%	-100%

Frequently Asked Questions

Growth & Financials

Inhibikase Therapeutics, Inc. (IKT) saw revenue decline by 100.0% over the past year.

Inhibikase Therapeutics, Inc. (IKT) reported a net loss of $47.7M for fiscal year 2024.

Dividend & Returns

Inhibikase Therapeutics, Inc. (IKT) has a return on equity (ROE) of -52.0%. Negative ROE indicates the company is unprofitable.

Inhibikase Therapeutics, Inc. (IKT) had negative free cash flow of $25.6M in fiscal year 2024, likely due to heavy capital investments.